MediPines Announces National Distribution for AGM100 Pulmonary Gas Exchange Technology

Designated by the World Health Organization (WHO) as one of 15 notably innovative health technologies for the treatment of COVID-19 and other global priority diseases in its 2021 edition of the WHO Compendium of Innovative Health Technologies, the AGM100 is currently being used at hospitals, medical rehabilitation centers and outpatient pulmonary clinics around the United States – from Pennsylvania to Florida to California, including key locations in the Midwest and Pacific coast. To meet growing demand, MediPines is making new units available to centers nationwide.

Rather than having to rely on surrogate measures for gas exchange, physicians using the AGM100 can directly measure patients’ pulmonary status at the bedside. The AGM100 is a medical device that rapidly detects respiratory impairment caused by conditions such as COVID-19, chronic obstructive pulmonary disease (COPD), pneumonia, ARDS, pulmonary edema or embolism, etc. This gas exchange measurement is performed non-invasively from a two-minute patient breathing sample method at the bedside. Respiratory results are available instantly on the screen as the patient is breathing naturally through a specialized mouthpiece connected to the analyzer system, similar to a “breathalyzer” test. The AGM100 is a portable system that can be used in emergency rooms, and respiratory and surgical departments throughout hospitals or any qualified health clinics.

With MediPines’ advanced, proprietary technology, clinicians are able to observe in real time how efficiently oxygen is being transported from outside air to patients’ alveoli, where the lung’s gas exchange takes place, and to their circulating blood, without a single needlestick or blood draw, a crucial step forward in respiratory assessment and monitoring during the COVID pandemic. Once a patient breathes normally through a specialized breathing circuit, the AGM100 quickly calculates and provides a comprehensive panel of respiratory measurements including blood oxygen levels, oxygen deficit (aka A-a gradient), P/F ratio, and alveolar oxygen and carbon dioxide levels. So, a full view of the patient’s respiratory status is achieved instantly.

“The AGM100 is an important scientific innovation for detecting respiratory impairment non-invasively,” said Dr. John B. West, M.D., Ph.D., D.Sc., leading global authority on respiratory physiology; Emeritus Professor of Medicine and Physiology at UC San Diego School of Medicine; and Medical Advisory Chair at MediPines. “It is especially relevant today because COVID attacks the parenchyma, the part of the lung where gas exchange occurs.”

“In the age of COVID we feel privileged to now offer AGM100 technology on a national level, with many large health systems and clinical centers of excellence in pulmonary care around the country adopting our innovation as part of their patient care best practices, consistent with our founding mission at MediPines to advance respiratory medicine,” said MediPines CEO and principle architect of the AGM100 respiratory system, Steve Lee. “As doctors and caregivers continue to seek ways to understand which COVID-19 patients are at greater risk, or which treatment option is best with objectivity, AGM100 provides an easy, non-invasive way to accomplish that goal via a fast, precise tool that directly measures the core of lung function.”

MediPines is a global market leader in respiratory assessment and monitoring of pulmonary gas exchange. The company mission is to advance respiratory medicine by providing physiology-based respiratory devices that enhance clinical effectiveness and achieve better patient outcomes. Learn more at medipines.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220119006024/en/